/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that abstracts on its investigational tyrosine kinase inhibitor candidates, glesatinib (MGCD265) and sitravatinib (MGCD516), will be presented at the 2016 American Society of ... Barchart, 1 week ago
Mirati Therapeutics To Present Abstracts On Pipeline Programs At 2016 ASCO Annual Meeting - BioSpace, 1 week ago
Mirati Therapeutics reports Q1 EPS ($1.13), consensus (99c) - Pettinga Financial Advisors, 3 weeks ago
2 images for "mirati"
MIRATI THERAPEUTICS, INC. FILES (8-K) Disclosing Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. Our 2016 Annual Meeting of Stockholders was held on May 18, 2016. We had 19,538,796 shares of common stock outstanding and entitled to vote as of March 24, 2016, the record date forEquities.com, 3 days ago CT ORDER - Mirati Therapeutics, Inc. (0001576263) (Filer) SEC, 1 week ago 10-Q - Mirati Therapeutics, Inc. (0001576263) (Filer) SEC Filings, 3 weeks ago Mirati Therapeutics, Inc. Files SEC Form DEF 14A, Other Definitive Proxy Statements (Apr. 19, 2016) Equities.com, 4 weeks ago
News Editor Mirati Therapeutics (NASDAQ:MRTX): Q1 EPS of -$1.13 misses by $0.14. Comments (0) Be the first to comment All (0) Author's Picks () Load All Comments DJIA (DIA) S&P 500 (SPY) ETF Hub ETF Screener: Search and filter by ...Seeking Alpha, 3 weeks ago
March 23 (Reuters) - * Mirati Therapeutics inc says prior to joining Mirati, donadio was with Amylin pharmaceuticals inc, most recently serving as senior director of finance * Mirati Therapeutics announces promotion of Jamie A. Donadio to ...Reuters UK, 2 months ago
Collaboration with Mirati Therapeutics targets MET gene mutations to4 Traders, 1 month ago QIAGEN Partners with Mirati Therapeutics, Inc. Advance for Respiratory Care & Sleep Medicine, 1 month ago QIAGEN Partners to Develop Novel Companion Diagnostic in Lung Cancer Sys-Con Canada, 1 month ago BRIEF-Qiagen Partners to develop novel companion diagnostic in lung cancer Reuters UK, 1 month ago
Mirati Therapeutics (NASDAQ: MRTX) has recently received a number of price target changes and ratings updates: 5/24/2016 Mirati Therapeutics had its outperform rating reaffirmed by analysts at Wedbush. They now have a $29.00 price target on the ...Ticker Report, 4 hours ago
Mirati Therapeutics (NASDAQ:MRTX) Rating Restated Wedbush currently has a $29.00 price target on the $335.63M market cap company or 72.00 % upside potential. In a note released on 24 May, Mirati Therapeutics (NASDAQ:MRTX) stock had its Outperform ...Octafinance, 2 days ago Mirati Therapeutics, Inc. (MRTX) Given New $29.00 Price Target at Wedbush American Banking News, 2 days ago Mirati Therapeutics, Inc. (MRTX) to Post FY2018 Earnings of ($5.58) Per Share, Wedbush Forecasts American Banking News, 6 hours ago Mirati Therapeutics, Inc. (MRTX) Stock Rating Reaffirmed by Wedbush SleekMoney, 16 hours ago
More from: American Banking News - Stock Ratings, American Banking News - Earnings...and 9 other sources
TIAA CREF Investment Management LLC continued to hold its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) during the first quarter, Holdings Channel reports. The fund owned 35,395 shares of the company's stock at the end of the first ...WKRB News, 19 hours ago Rhenman & Partners Asset Management AB Continues to Hold Stake in Mirati Therapeutics, Inc. (MRTX) Ticker Report, 2 days ago
| CEOWORLD Financial | Chief Executive Forum Register Now Lost Password Lost your password? Please enter your email address. You will receive a link and will create a new password via email. May 17, 2016 at 09:27 AM EDT ...CEOWorld Magazine, 1 week ago
A number of firms have modified their ratings and price targets on shares of Mirati Therapeutics (NASDAQ: MRTX) recently: 5/12/2016 Mirati Therapeutics is now covered by analysts at Piper Jaffray. They set a hold rating and a $17.00 price target on ...Ticker Report, 1 week ago
on your WebpageAdd Widget >Get your members hooked!